Reporting, analysis and commentary on Celcuity from Speedway Scene, drawn together from across our coverage.
Gedatolisib, Celcuity's PI3K/mTOR inhibitor, faces a July 17, 2026 FDA decision that could deliver the first targeted therapy for HR-positive, PIK3CA wild-type advanced breast cancer patients with no options after CDK4/6 and hormone therapy.
This archive gathers Speedway Scene coverage of Celcuity, bringing together the reporting, analysis and commentary connected to the subject.
The essential morning briefing on the markets, business and world developments that shape the day ahead.
